[1] Wang CW, Li YY, Zhu SG, et al. Surgical management and evaluation of prognostic factors influencing postoperative visual outcome of suprasellar meningiomas. World Neurosurg. 2011. 75(2): 294-302.
[2] Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012. 77(5-6): 713-24.
[3] Ajlan AM, Choudhri O, Hwang P, Harsh G. Meningiomas of the tuberculum and diaphragma sellae. J Neurol Surg B Skull Base. 2015. 76(1): 74-9.
[4] Nanda A, Ambekar S, Javalkar V, Sharma M. Technical nuances in the management of tuberculum sellae and diaphragma sellae meningiomas. Neurosurg Focus. 2013. 35(6): E7.
[5] Shen CC, Wang YC, Hua WS, Chang CS, Sun MH. Endoscopic endonasal transsphenoidal surgery for pituitary tumors. Zhonghua Yi Xue Za Zhi (Taipei). 2000. 63(4): 301-10.
[6] Cappabianca P, Cirillo S, Alfieri A, et al. Pituitary macroadenoma and diaphragma sellae meningioma: differential diagnosis on MRI. Neuroradiology. 1999. 41(1): 22-6.
[7] Kwancharoen R, Blitz AM, Tavares F, Caturegli P, Gallia GL, Salvatori R. Clinical features of sellar and suprasellar meningiomas. Pituitary. 2014. 17(4): 342-8.
[8] Donovan JL, Nesbit GM. Distinction of masses involving the sella and suprasellar space: specificity of imaging features. AJR Am J Roentgenol. 1996. 167(3): 597-603.
[9] Zaidi HA, Cote DJ, Castlen JP, et al. Time Course of Resolution of Hyperprolactinemia After Transsphenoidal Surgery Among Patients Presenting with Pituitary Stalk Compression. World Neurosurg. 2017. 97: 2-7.
[10] Castlen JP, Cote DJ, Zaidi HA, Laws ER Jr. The extended, transnasal, transsphenoidal approach for anterior skull base meningioma: considerations in patient selection. Pituitary. 2017. 20(5): 561-568.
[11] Kawamata T, Iseki H, Shibasaki T, Hori T. Endoscopic augmented reality navigation system for endonasal transsphenoidal surgery to treat pituitary tumors: technical note. Neurosurgery. 2002. 50(6): 1393-7.
[12] Koutourousiou M, Fernandez-Miranda JC, Wang EW, Snyderman CH, Gardner PA. Endoscopic endonasal surgery for olfactory groove meningiomas: outcomes and limitations in 50 patients. Neurosurg Focus. 2014. 37(4): E8.
[13] Morales-Valero SF, Van Gompel JJ, Loumiotis I, Lanzino G. Craniotomy for anterior cranial fossa meningiomas: historical overview. Neurosurg Focus. 2014. 36(4): E14.
[14] Al-Mefty O, Holoubi A, Rifai A, Fox JL. Microsurgical removal of suprasellar meningiomas. Neurosurgery. 1985. 16(3): 364-72.
[15] Kim YH, Wang KC, Phi JH, Kim SK. Endoscopic Endonasal Approach for Suprasellar Lesions in Children: Complications and Prevention. J Korean Neurosurg Soc. 2017. 60(3): 315-321.
[16] Koutourousiou M, Fernandez-Miranda JC, Stefko ST, Wang EW, Snyderman CH, Gardner PA. Endoscopic endonasal surgery for suprasellar meningiomas: experience with 75 patients. J Neurosurg. 2014. 120(6): 1326-39.
[17] Turel MK, Tsermoulas G, Reddy D, Andrade-Barazarte H, Zadeh G, Gentili F. Endonasal endoscopic transsphenoidal excision of tuberculum sellae meningiomas: a systematic review. J Neurosurg Sci. 2016. 60(4): 463-75.
[18] Hershey BL. Suprasellar masses: diagnosis and differential diagnosis. Semin Ultrasound CT MR. 1993. 14(3): 215-31.
[19] Yi C, Yu D, Shi X, et al. The combination of 13N-ammonia and 18F-FDG whole-body PET/CT on the same day for diagnosis of advanced prostate cancer. Nucl Med Commun. 2016. 37(3): 239-46.
[20] Jadvar H. Molecular imaging of prostate cancer: PET radiotracers. AJR Am J Roentgenol. 2012. 199(2): 278-91.
[21] Xiangsong Z, Weian C, Dianchao Y, Xiaoyan W, Zhifeng C, Xiongchong S. Usefulness of (13)N-NH (3) PET in the evaluation of brain lesions that are hypometabolic on (18)F-FDG PET. J Neurooncol. 2011. 105(1): 103-7.
[22] Zhao S, Kuge Y, Mochizuki T, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 2005. 46(4): 675-82.
[23] Bergström M, Muhr C, Lundberg PO, Långström B. PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med. 1991. 32(4): 610-5.
[24] Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J Nucl Med. 2011. 52(4): 547-50.
[25] Xiangsong Z, Xinjian W, Yong Z, Weian C. 13N-NH3: a selective contrast-enhancing tracer for brain tumor. Nucl Med Commun. 2008. 29(12): 1052-8.
[26] Xiangsong Z, Weian C. Differentiation of recurrent astrocytoma from radiation necrosis: a pilot study with 13N-NH3 PET. J Neurooncol. 2007. 82(3): 305-11.
[27] Shi X, Zhang X, Yi C, Wang X, Chen Z, Zhang B. The combination of 13N-ammonia and 18F-FDG in predicting primary central nervous system lymphomas in immunocompetent patients. Clin Nucl Med. 2013. 38(2): 98-102.
[28] Boksha IS, Tereshkina EB, Burbaeva GS. Glutamine synthetase and glutamine synthetase-like protein from human brain: purification and comparative characterization. J Neurochem. 2000. 75(6): 2574-82.
[29] Ott P, Larsen FS. Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. Neurochem Int. 2004. 44(4): 185-98.
[30] Phelps ME, Hoffman EJ, Coleman RE, et al. Tomographic images of blood pool and perfusion in brain and heart. J Nucl Med. 1976. 17(7): 603-12.
[31] McCormick D, McQuaid S, McCusker C, Allen IV. A study of glutamine synthetase in normal human brain and intracranial tumours. Neuropathol Appl Neurobiol. 1990. 16(3): 205-11.
[32] Spampinato MV, Smith JK, Kwock L, et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol. 2007. 188(1): 204-12.